Reported Earlier, Arcutis Expands ZORYVE Label With FDA Approval For Once-Daily Steroid-Free Plaque Psoriasis Treatment In Young Children
Benzinga Newsdesk 4 months ago
News
ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of ageZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the
- ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of age
- ZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the body with no restrictions on duration of use
- Seventh FDA approval for ZORYVE in four years